Previous close | 183.42 |
Open | 203.02 |
Bid | 217.76 x 800 |
Ask | 217.95 x 900 |
Day's range | 201.86 - 218.38 |
52-week range | 132.24 - 243.52 |
Volume | |
Avg. volume | 1,018,314 |
Market cap | 32.074B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 36.16 |
EPS (TTM) | 6.03 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | 1.92 (1.05%) |
Ex-dividend date | 07 Feb 2024 |
1y target est | 202.68 |
ResMed stock jumped Friday after crushing sales estimates and wiping out worries that weight-loss drugs would squeeze sleep apnea device sales.
Integer Holdings' (ITGR) first-quarter results reflect robust Medical Sales, along with strength in all the product lines.
STOCKSTOWATCHTODAY BLOG Shares of ResMed were trading sharply higher after the medical devices company filed a quarterly report that left Wall Street cheering. On Friday, ResMed stock was rising 14% to $209.